Company: CRL
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001100682-25-000043
Chunk: 42

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 2
Chunk 42
---
(in thousands)Proceeds from long-term debt and revolving credit facility$1,070,861 $976,783 Payments on long-term debt, revolving credit facility, and finance lease obligations(1,141,500)(1,316,990)Proceeds from exercises of stock options 3 23,110 Purchase of treasury stock(360,577)(119,051)Payment of contingent consideration(21,822)— Purchase of remaining equity interest of other redeemable noncontrolling interest(19,140)(12,000)Other, net(12,687)(26,900)Net cash used in financing activities$(484,862)$(475,048)

Financing activities primarily consist of the proceeds and repayments of debt and certain equity related transactions including treasury stock purchases and employee stock option exercises.

For the nine months ended September 27, 2025, net cash used in financing activities was primarily driven by the following activity:

•Net repayments of $60.5 million from our Credit Facility

•Treasury stock purchases of $350.0 million associated with our stock repurchase program and $9.9 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

•Payment of $21.8 million associated with contingent consideration related to the acquisition of Noveprim

•Payment of $19.1 million for the remaining 8% equity interest in Vital River

For the nine months ended September 28, 2024, net cash used in financing activities was primarily driven by the following activity:

•Net repayments of $346.2 million from our Credit Facility

•Treasury stock purchases of $100.7 million associated with our stock repurchase program and $18.4 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

•Net proceeds from exercises of employee stock options of $23.1 million

•Net dividend payments to noncontrolling interest holders of $14.5 million

•Payment of $12.0 million for the remaining 10% equity interest in an other redeemable noncontrolling interest

36 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Financing and Market Risk

We are exposed to market risk from changes in interest rates and currency exchange rates, which could affect our future results of operations and financial condition. We manage our exposure to these